Sepetaprost is an investigational new drug that is being evaluated for the treatment of open angle glaucoma and ocular hypertension. It is an agonist of the prostaglandin EP3 and F receptors.
As of 2025 Sepetaprost is registered in Japan as Setaneo ophthalmic solution 0.002%, sold by Santen Pharmaceuticals. It is indicated for the treatment of glaucoma and ocular hypertension.